Daratumumab targets CD38 on myeloma and some immune cells, causing immune activation and infusion-related reactions (fever, chills, respiratory issues), as well as hematologic toxicities (neutropenia, thrombocytopenia, anemia), increasing infection risk. Here, CD38 is linked to anemia (phenotype).